Published On: December 2022
The market for cardiac biomarkers was estimated to be worth USD 13.98 billion in 2021. It is expected to increase at a CAGR of 14.7% from 2022 to 2030, per the cardiac biomarkers market outlook.
Cardiac biomarkers are protein-based substances that can be measured for heart disease prognostic and diagnostic analyses. When the heart is stressed or injured, like when there is insufficient oxygen in the blood, cardiac biomarkers are released into the body. Acute coronary syndrome (ACS), myocardial ischemia, and other cardiovascular diseases can be diagnosed via measurements of cardiac biomarkers such as cardiac troponin, myoglobin, creatinine kinase, and others.
The development of plaque in the arteries leads to the narrowing of arterial walls, which is the cause of ACS. When a plaque ruptures, oxygenated blood that reaches the heart suddenly drops. A lack of blood causes chest pain that lasts a long time. Conversely, myocardial ischemia limits the heart muscles' capacity to pump as much blood as the heart cells need. A decrease in blood flow brings on chest pain, perspiration, and other symptoms. Heart cells may die if blood flow is cut off for an extended period. Heart attack or acute myocardial infarction (AMI) are terms used to describe this situation. Uneven heartbeats, commonly known as irregular heartbeats, might result from permanent heart muscle injury.
The COVID-19 pandemic had a massive effect on the market. The complex instances of COVID-19 had elevated cardiac damage biomarkers. The worst result has an inverse relationship with this elevation. Examining cardiac biomarkers with signs of other organ damage offers a more reliable tool for case deaths and outcomes. But according to the study "Cardiovascular Biomarkers in Patients with COVID-19," biomarkers measuring cardiovascular pathophysiologies, like cardiomyocyte injury and cardiac hemodynamic stress, are strongly associated with the death risk in patients with primarily non-cardiac disorders, like pneumonia brought on by SARS-CoV-2.
The market for cardiac biomarkers is being stimulated by the growing prevalence of cardiovascular disorders, the creation of cardiac biomarkers, and rising funding for research and development. For instance, a WHO report from July 2021 estimates that 17.9 million people die from heart disease each year worldwide. This accounts for 31% of all deaths worldwide. It is anticipated that the increasing frequency of cardiovascular diseases will increase the need for early detection and treatment.
The use of cardiac biomarkers as a comprehensive diagnostic strategy for numerous cardiovascular disorders is very common. The market for cardiac biomarkers is primarily driven by the rising prevalence of cardiovascular diseases and lifestyle illnesses, the rise in demand for disease-specific treatments and research that use cardiac biomarkers, technological advancements in cardiac biomarkers, and supportive government initiatives to raise public awareness of cardiovascular illnesses.
Cardiac biomarkers are frequently employed as a comprehensive diagnostic strategy for various cardiovascular illnesses. According to the cardiac biomarkers market analysis, the market for cardiac biomarkers is primarily propelled by the rising prevalence of cardiovascular diseases and lifestyle illnesses, the rise in demand for disease-specific treatment and research that uses cardiac biomarkers, technological advancements in cardiac biomarkers, and supportive government initiatives to raise awareness of cardiovascular illnesses. But it's anticipated that a lack of public awareness would impede industry expansion.
Expected High Growth in Troponin
Troponin tests are becoming a profitable market due to their advantages in detecting myocardial infarction and congestive heart failure and their superiority in diagnosing cardiovascular disorders in a timely and accurate manner compared to other tests. The definitive blood test for assessing patients suspected of suffering an acute myocardial infarction and cardiac heart failure is cardiac troponins, according to a study by Saikrishna Patibandla published in the National Library of Medicine in August 2021. They are sensitive and precise biomarkers of myocardial ischemia, which explains why. Sensitive and very sensitive assays can be used to find cardiac troponin levels in the blood.
Per the cardiac biomarkers market analysis, the market for troponin biomarkers is expected to be propelled by the rising prevalence of cardiac disorders. For instance, a myocardial infraction occurs every 40 seconds in the United States, with an estimated annual incidence of 605,000 new cases, 200,000 recurrent cases, and a prevalence of 3.0% among adults aged 20 and older, according to a study by Bin Yu et al. published in Frontiers in Cardiovascular Medicine in September 2021.
The creation of ground-breaking products for the treatment of cardiovascular disorders is a major priority for many businesses. For instance, Siemens Healthineers' cardiac troponin point-of-care test received the CE Mark in April 2021. The Atellica VTLi Patient-Side Immunoassay Analyzer provides the point-of-care test for heart attacks.